Mangoceuticals, Inc. Stock Price, News & Analysis

Mangoceuticals (NASDAQ: MGRX) has announced significant progress in its H1N1 efficacy study, reporting a substantial reduction in viral load during Phase 1 animal trials. The company is now advancing to the next research stage while simultaneously expanding its focus to include H5N1 (Avian Influenza) studies.

The research, conducted by Vipragen Biosciences in India, utilizes Mangoceuticals' proprietary formulation combining advanced polyphenol and zinc chemistry. The H5N1 cohort will run concurrently with the ongoing H1N1 study, demonstrating the company's commitment to addressing multiple respiratory illness threats.

The company plans to disclose final results after completing the studies and securing proper intellectual property protections through provisional filings.

Mangoceuticals (NASDAQ: MGRX) has entered into an exclusive Master Distribution Agreement with Propre Energie for Dermytol®, a clinically proven skincare treatment targeting hyperpigmentation. The agreement grants MGRX exclusive rights to market, sell, and distribute Dermytol® across North and South America.

Dermytol® is an advanced, plant-based formula proven more effective than Kojic acid at reducing melanin production while causing less damage to skin cells. The product utilizes a proprietary blend of ingredients including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera.

The partnership targets the growing global skincare market, projected to reach $218 billion by 2029 with a 3.61% CAGR. The plant-based skincare segment specifically is expected to grow from $789.75 million in 2023 to $1.62 billion by 2033, representing a 7.5% CAGR.

Mangoceuticals (NASDAQ: MGRX) has acquired patent WO 2023/086647 PCT/US2022/049857 for mushroom-derived compositions and treatment methods. The patent covers nutraceutical formulations from functional mushrooms including Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion's Mane), designed to enhance immune function, cognitive performance, mood, and provide adaptogenic benefits.

The company plans to develop new wellness products leveraging this patent, including dietary supplements and functional foods. The acquisition aligns with the growing functional mushroom market, which is valued at $32.41 billion in 2024 and projected to reach $48.59 billion by 2029, with a CAGR of 8.44% according to Mordor Intelligence.

Mangoceuticals (NASDAQ: MGRX) has initiated an investigation into potential stock manipulation following its October 16, 2024 reverse stock split. The company identified suspicious trading patterns and an unusual surge in shareholder accounts. The Depository Trust Company (DTC) requested 213,327 additional shares for fractional share 'round-up', representing about 9% of MangoRx's 2.4 million post-split outstanding shares.

Prior to the split, MangoRx had approximately 5,000 shareholders, but trading patterns suggest a potential increase of over 200,000 accounts post-split. The company observed numerous high-frequency single-share transactions around the split date. CEO Jacob Cohen has denied DTC's request pending investigation completion. MangoRx notes similar patterns to those reported by Upexi Inc. (NASDAQ:UPXI), which experienced comparable irregularities in their recent reverse stock split.

Mangoceuticals (NASDAQ: MGRX) has regained full compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on October 30, 2024, stating that its common stock maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, meeting the requirements of Nasdaq Listing Rule 5550(a)(2). With this compliance achievement, the listing matter is now closed.

MangoRx (NASDAQ: MGRX), a company specializing in men's health and wellness products via telemedicine, has announced the formation of a Strategy and Alternatives Committee. The company's Board of Directors has initiated a process to evaluate potential strategic alternatives aimed at maximizing shareholder value.

These alternatives may include mergers, acquisitions, divestitures, business combinations, entry into new lines of business, expansions, and joint ventures. This initiative will run parallel to MangoRx's current operations. The company plans to consult with financial and legal advisors to consider a wide range of strategic, operational, and financial options.

MangoRx has not set a timeline for completing this review process and does not intend to provide further comments unless necessary. The company emphasizes that there is no guarantee that this strategic review will result in any specific transaction or outcome.

MangoRx (NASDAQ: MGRX), a company focused on men's health and wellness products, has responded to claims made by Eli Lilly. Eli Lilly has allegedly filed a lawsuit against MangoRx, claiming that the company improperly copied its weight-loss medicines, Zepbound and Mounjaro. MangoRx strongly refutes these claims regarding the sale of compounded tirzepatide and intends to vigorously defend itself.

The company believes it has strong arguments against Eli Lilly's claims and remains committed to providing access to safe and efficacious products prescribed by U.S. licensed practitioners. MangoRx plans to continue enhancing patient care through innovative solutions while striving to comply with regulatory guidelines.

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, has announced its participation in the Centurion One Capital 2nd Annual Bahamas Summit 2024. The event will take place at the Rosewood Baha Mar Hotel in Nassau, Bahamas, from October 22nd to 23rd, 2024.

Jacob Cohen, Founder and CEO of Mangoceuticals, is scheduled to present on Wednesday, October 23rd at 11:10 EDT. He will also be available to field investor questions during the summit. The event will feature presentations from public and private companies across various industries, providing opportunities to showcase their businesses to prominent investors in the growth space from Canada, the United States, and abroad.

Mangoceuticals (NASDAQ: MGRX), a company focused on men's health and wellness products, has announced a 1-for-15 reverse stock split effective October 16, 2024. This move is part of the company's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse split will reduce MGRX's outstanding common stock from approximately 35.5 million shares to 2.4 million shares. The trading symbol will remain 'MGRX'. All outstanding options and securities will be adjusted accordingly, and no fractional shares will be issued. This decision follows stockholder approval at a Special Meeting on March 25, 2024.